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Introduction

Results

❖ Uveal melanoma is the most common primary intraocular malignant tumor in adults.
❖ Up to half of all patients develop systemic metastases, with liver involvement in >90% of
patients.1
❖ Various liver-directed, locoregional therapies (i.e. chemoembolization, immunoembolization,
radioembolization, and ablation) have played a significant role in prolonging the lives of
patients with metastatic uveal melanoma.2
❖ Elevated bilirubin levels are typically considered a relative contraindication for lobar hepatic
arterial embolization treatment, given mainly the increased risk of precipitating hepatic
failure.
❖ Gilbert's syndrome, also known as benign unconjugated hyperbilirubinemia, is a hereditary
disorder of bilirubin conjugation. Gilbert’s syndrome leads to elevated levels of serum
bilirubin, that do not truly reflect cholestasis or liver failure and therefore should not exclude
patients from targeted embolization therapy.3

❖ Of the 99 procedures, 67 (68%) were performed with elevated pre-treatment total serum
bilirubin levels (>1). 63 (64%) had pre-treatment total serum bilirubin levels from 1-2 mg/dL,
3 (3%) had pre-treatment levels from 2.1-3 mg/dL, and 1 (1%) had a pre-treatment level
>3 mg/dL (max 3.8).

❖ Immediate post-procedure liver toxicities based on the NCI CTCAE (National Cancer
Institute Common Terminology Criteria for Adverse Events) were documented for
96 procedures.

❖ Pre- and Post-embolization total serum bilirubin levels were evaluated in all 11 patients
(Table 1)
➢ Overall total serum bilirubin increased a median value of 13%.
➢ Direct bilirubin levels increased a median value of 7%.
➢ Indirect bilirubin levels increased a median value of 11%.

Table 1

Objectives

❖ Evaluate the safety of lobar
hepatic artery treatment in
patients with metastatic uveal
melanoma and a diagnosis of
Gilbert's disease.

❖ Compare pre- and postembolization liver function tests
in patients undergoing lobar
hepatic arterial embolization.

❖ Longitudinal post-embolization laboratory values were available for 72 procedures.
Normalization of total serum bilirubin levels to baseline values (equivalent to levels
within 0.5 mg/dL or less of pre-embolization values) occurred on average 7.5 days
post-embolization (range 6 - 20 days).
❖ Pre- and Post-embolization total serum bilirubin levels over a single patient’s 19 treatments
(Table 2)
➢ Overall total serum bilirubin increased a median value of 20%.
➢ Direct bilirubin levels increased a median value of 50%.

❖ Describe complications rates
and mortality of patients
evaluated in the study.

➢ Indirect bilirubin levels increased a median value of 20%.

Table 2
Digital Subtraction Angiography of the Celiac Artery: Multiple Hypervascular
Hepatic Tumor Blushes representing Uveal Melanoma Metastasis

❖ Of the 72 procedures with available longitudinal laboratory data, 90% (n=65) did not
demonstrate a total serum bilirubin elevation of greater than 0.5 mg/dL above
pre-embolization values.
❖ No toxicity prevented future embolotherapy in these patients. No deaths occurred
within 30 days following treatment.

Conclusion
❖ To our knowledge this has been the first outcome analysis of patients undergoing hepatic
lobar arterial embolization with underlying Gilbert’s syndrome.
❖ Hepatic artery embolization is well tolerated in patients with underlying Gilbert's disease and
these patients should not be excluded for treatment based solely on laboratory values.

Materials and Methods
❖ Institution IRB approved retrospective chart review of 11 patients with hyperbilirubinemia
attributed to Gilbert’s disease.
❖ September 2003 - May 2016.
❖ Ninety-nine (99) embolization procedures performed on these 11 patients including:
chemoembolization (42 procedures), immunoembolization (54 procedures), and
radioembolization (3 procedures).
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